Pharmacogenomic strategy for individualizing antidepressant therapy

Dialogues in Clinical Neuroscience

Volumn 10, Issue 4, 2008, Pages 401-408

  Lin, Keh Ming ^a,b   Perlis, Roy H ^c   Wan, Yu Jui Yvonne ^d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b STANFORD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Individualized medicine; Personalized medicine; Pharmacogenetic; Pharmacogenomic; Psychopharmacology; Treatment response

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; OROSOMUCOID; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; ASIAN; CAUCASIAN; CHINESE; COMPUTER MODEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSFORMATION; FINANCIAL MANAGEMENT; FUZZY SYSTEM; GENE DELETION; GENE INSERTION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ORGANIZATION; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL PRACTICE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROMOTER REGION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; HUMANS; PHARMACOGENETICS; PILOT PROJECTS;

EID: 59149085326     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276:293-299.
3. Desjarlais R, Eisenberg L, Good B, Kleinman A. World Mental Health: Problems and Priorities in Developing Countries. New York, NY: Oxford University Press US; 1995.
4. Guze SB, Robins ELI. Suicide and primary affective disorders. Br J Psychiatry. 1970;117:437.
5. Wells KB, Sturm RS, Sherbourne CD, Meredith LS. Caring for Depression: a RAND Study: Cambridge, MA: Harvard University Press; 1996.
6. Penninx BWJH, Beekman ATF, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. 2001;58:221-227.
7. May M, McCarron P, Stansfeld S, et al. Does psychological distress predict the risk of ischemic stroke and transient ischemic attack? The Caerphilly Study. Stroke. 2002;33:7-12.
8. Judd LL, Martin PP, Wells KB, Rapaport MH. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry. 1996;153:1411-1417.
9. Sherbourne CD, Wells KB, Hays RD. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am J Psychiatry. 1994;1:1-2.
10. Lundqvist E, Johansson I, Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999;226:327-338.
11. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(suppl):38-45; discussion 46-37.
12. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435-443.
13. Harper PA, Wong JMY, Lam MSM, Okey AB. Polymorphisms in the human AH receptor. Chemico-Biological Interactions. 2002;141:161-187.
14. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 2001;1:59-64.
15. Saito S, Iida A, Sekine A, et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet. 2002;47:38-50.
16. Baumann P, Eap CB, Muller WE, Tillement JP. Alpha-Acid Glycoprotein: Genetics, Biochemisty, Physiological Functions and Pharmacology. New York, NY: Alan R. Liss, Inc; 1989.
17. Duché JC, Urien S, Simon N, Malaurie E, Monnet I, Barr J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem. 2000;33:197-202.
18. Barker EL, Blakely RD. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress, New York, NY: Raven Press; 1995:321-333.
19. Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 1999;46:1301-1308.
20. Schatzberg AF, Schildkraut JJ. Recent studies on norepinephrine systems in mood disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York, NY: Raven Press; 1995:911-920.
21. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531.
22. Greenberg BD, McMahon FJ, Murphy DL. Serotonin transporter candidate gene studies in affective disorders and personality: promises and potential pitfalls. Mol Psychiatry. 1998;3:186-189.
23. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400-403.
24. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry. 2002;7:1115-1119.
25. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511.
26. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23:587-590.
27. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry. 2001;6:586-592.
28. Rausch JL, Johnson ME, Fei YJ, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry. 2002;51:723-732.
29. Zanardi R, Serretti A, Rossini D, et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50:323-330.
30. Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. NeuroReport. 2000;11:215.
31. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383-386.
32. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology. 2004;174:525-529.
33. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry. 2001;58:539-544.
34. Perlis RH, Wan YY, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Paper presented at: American College of Neuropsychopharmacology. San Juan, Puerto Rico; 2002.
35. Massat I, Souery D, Lipp O, et al. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. Am J Med Genet. 2000;96:136-140.
36. Serretti A, Lilli R, Lorenzi C, Smeraldi E. No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. Psychiatry Res. 1999;86:203-209.
37. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C Polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis. 1999;6:433-439.
38. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet. 2000;96:56-60.
39. Tiihonen J, Kuikka J, Bergstrom K, et al. Altered striatal dopamine reuptake site densities in habitually violent and non-violent alcoholics. Nat Med. 1995;1:654-657.
40. Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene(DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14:1104-1106.
41. Muramatsu T, Higuchi S. Dopamine transporter gene polymorphism and alcoholism. Biochem Biophys Res Commun. 1995;211:28-32.
42. Parsian A, Zhang ZH. Human dopamine transporter gene polymorphism (VNTR) and alcoholism. Am J Med Genet. 1997;74:480-482.
43. Sander T, Harms H, Podschus J, et al. Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Biol Psychiatry. 1997;41:299-304.
44. Inada T, Sugita T, Dobashi I, et al. Dopamine transporter gene polymorphism and psychiatric symptoms seen in schizophrenic patients at their first episode. Am J Med Genet. 1996;67:406-408.
45. Barr CL, Xu C, Kroft J, et al. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2001;49:333-339.
46. Greenwood TA, Alexander M, Keck PE, et al. Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder. Am J Med Genet. 2001;105:145-151.
47. Schramm NL, McDonald MP, Limbird LE. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci. 2001;21:4875-4882.
48. González-Maeso J, Rodríguez-Puertas R, Meana JJ, García-Sevilla JA, Guimón J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha 2A-adrenoceptors. Mol Psychiatry. 2002;7:755-767.
49. Schittecatte M, Dumont F, Machowski R, et al. Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha2-adrenergic receptors in depression. Psychiatry Res. 2002;109:1-8.
50. Marazziti D, Baroni S, Masala I, et al. Correlation between platelet alpha-adrenoreceptors and symptom severity in major depression. Neuropsychobiology. 2001;44:122-125.
51. Zill P, Baghai TC, Engel R, et al. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response. Am J Med Genet. 2003;120B:85-89.
52. Szegedi A, Rujescu D, Tadic A, et al. The catechol-O-methyltransferase Val108//158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2004;5:49-53.
53. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998;103:273-279.
54. Kunugi H, Ishida S, Kato T, et al. A functional polymorphism in the promoter region of monoamine oxidase-A gene and mood disorders. Mol Psychiatry. 1999;4:393-395.
55. Ibanez A, Perez de Castro I, Fernandez-Piqueras J, Saiz-Ruiz J. Association between the low-functional MAO-A gene promoter and pathological gambling. Am J Med Genet. 2000;96:464-465.
56. Bellivier F, Leboyer M, Courtet P, et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry. 1998;55:33-37.
57. Nielsen DA, Virkkunen M, Lappalainen J, et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry. 1998;55:593-602.
58. Serretti A, Lorenzi C, Cusin C, et al. SSRIs antidepressant activity is influenced by G,3 variants variants. Eur Neuropsychopharmacol. 2003;13:117-122.
59. Murphy GM, Kremer C, Rodrigues H, Schatzberg AF. The apolipoprotein E e4 allele and antidepressant efficacy in cognitively intact elderly depressed patients. Biol Psychiatry. 2003;54:665-673.
60. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des. 2005;11:1495-1510.